tbuckley/cabot-search huggingface dataset:
Role of IL-4-Producing CD8+ T Cells in Patients with Chronic Graft-Versus-Host Disease (cGVHD) and in Normal Healthy Volunteer.
Authors: Kengo Nakamura, Masashi Takebayashi, Kenichirou Tajima, Tsutomu Tanijiri, Takashi Yokoi, Yonsu Son, Noriaki Matsumoto, Katsuhiro Zen, Yuji Kishimoto, Ryuichi Amakawa, Shirou Fukuhara
Journal: Blood (2004)
Interim Analysis of a Prospective Randomised Study Comparing a Therapeutic Platelet Transfusion Strategy with the Prophylactic Platelet Transfusion Standard in Patients after Autologous Peripheral Stem Cell Transplantation (ASCT).
Authors: Kerstin Schaefer-Eckart, Knut Wendelin, Martin Wilhelm, U. Mahlknecht, R. Conradi, M. Schaich, L. Leimer, Hannes Wandt
Journal: Blood (2006)
Balancing efficacy with tolerability: The conversational mechanics of shared decision making in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Lorie Ellis, Brad Davidson, Matthew DiChiara, Mekre Senbetta
Journal: Journal of Clinical Oncology (2012)

229 Background: Discussions of therapeutic risk or benefit have a different tone in patients facing metastatic cancer. The literature predicts misalignment on therapy selection and communication gaps between patients and physicians. Gaps in assumed reasons for therapy selection may hinder the mCRPC patient’s ability to make fully informed decisions. (Fine, E. et al; J. Palliative Med, 2010, 13(5); 595-603.) Methods: This IRB-approved, observational, linguistic study describes naturally occurring conversations between mCRPC patients (n=42; 69% African American) and their treating urologist (n=7) or oncologist (n=7) during a normal clinic visit in Summer 2011. Clinic interactions were videotaped without 3 rd party observers present. Patients and physicians were interviewed again separately after the clinic visit. All conversations were transcribed and analyzed using standard techniques from anthropology and discourse analysis fields. Results: At both a lexical and goal-oriented level, several disparities were observed. When discussing treatment options and goals for mCRPC, lexically, words used by physicians differed from those used by patients. This difference was found in physicians’ use of technical language and in language describing goals and results of therapy. Of interest, physicians consistently used vague language to describe therapeutic effect (e.g. “working”), and frequently presented treatment options without presenting treatment risks (e.g. “maybe go to another treatment altogether”). Patients and physicians also differed in the way they framed goals of therapy. Conclusions: The current research highlights communication gaps between clinicians and mCRPC patients about treatment options and risks. These results suggest that patient decision making may be hindered by a lack of clear understanding of treatment choice implications and poorly defined treatment goals. Treatments with an optimum balance of efficacy and tolerability may present an opportunity to improve this dialogue.
Bendamustine, Rituximab and Bortezomib Combined with Liposomal Ara-C (DepoCyte®) for CNS Prophylaxis in Relapsed/Refractory Dlbcl: A Case Report
Authors: Fabio Ardizzone, Michele Sciacca, Paola Migliora, Cristina Ravanelli, Alberto Santagostino
Journal: Blood (2008)
CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study
Authors: Deborah L White, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, Fabrizio Pane, Giovanni Martinelli, Jerald Radich, Thea Kalebic, Giuseppe Saglio, Timothy Hughes
Journal: Blood (2008)
Promoting consultation recording practice in oncology: Identification of critical implementation factors and determination of patient benefit.
Authors: Thomas F Hack, Joseph D. Ruether, Lorna Weir, Debjani Grenier, Lesley F Degner
Journal: Journal of Clinical Oncology (2012)

155 Background: The objectives of this implementation study were to 1) identify and address the evidentiary, contextual, and facilitative mechanisms that serve to retard or promote the transfer and uptake of consultation recording use in oncology practice, and 2) follow patients during the first few days following receipt of the consultation recording to document, from the patient’s perspective, the benefits realized from listening to the recording. Methods: Nine medical and 9 radiation oncologists from cancer centers in three Canadian cities (Calgary, Vancouver, Winnipeg) recorded their primary treatment consultations for 228 patients newly diagnosed with prostate or breast cancer. The Digital Recording Use Semi-Structured Interview (DRUSSI) was conducted at two days post-consultation and at 1-week post-consultation. Each oncologist was given a feedback letter summarizing the consultation recording benefits reported by their patients. Results: Sixty-nine percent of patients listened to at least a portion of the recording within the first week following the consultation. Consultation recording favourableness ratings were high: 93.6% rated the intervention between 75–100 on a 100-point scale. Four main areas of benefit were reported: 1) Anxiety reduction; 2) Enhanced retention of information; 3) Better informed decision making; and 4) Improved communication with family members. Eight fundamental components of successful transfer and uptake of consultation recording practice were identified. Conclusions: Implementation research and additional randomized trials are needed to facilitate the transfer and uptake of consultation recording use so that far more patients and significant others may realize the associated benefits.
Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.
Authors: C. Takita, I. M. Reis, F. Miao, K. E. LaFave, V. Gunaseelan, J. Hurley, O. E. Silva, E. Avisar, J. L. Wright
Journal: Journal of Clinical Oncology (2011)

112 Background: Triple-negative (basal) and HER2+ subtypes have been associated with increased risk of locoregional recurrence (LRR) in earlier studies of breast-conserving therapy (BCT), in which fewer patients received systemic therapy compared with recent standards, including HER2-targeted therapy. We analyzed whether basal and HER2+ subtypes are independent prognostic factors for LRR in BCT patients treated with modern systemic therapy. Methods: We retrospectively studied 415 patients with invasive breast cancer who received BCT from 1992 to 2009. Axillary surgery was done in 404 patients (97%). Forty eight percent of patients received chemotherapy (anthracycline/taxane 34%, trastuzumab-containing 4%, other 10%). Hormone therapy was given in 67%. Progression-free survival (PFS) and OS were estimated by the Kaplan-Meier method. Rate of LRR was estimated by the method of cumulative incidence allowing for competing risks. The effect of prognostic factors was examined by Fine and Gray’s test. Results: Median follow-up was 60 months. Median age was 54 (26–86). Stage: T1 70%, T2 26.3%, T3 8%; N0 75%, N1 23.5%, N2 1.7%. Receptor status was available in 301 patients to approximate subtypes: 66% Luminal A, 9% Luminal B, and 5% HER2+, and 20% Basal. Overall, there were 11 LRR, 15 distant metastasis, and 20 deaths. The 10-year PFS and OS were 85.4% and 90.5%, respectively. The 5 and 10-year cumulative incidence of LRR were 2.8% (95%CI: 1.4–5.2) and 4.5% (95%CI: 2.2–8.2) respectively. On univariate analysis, Basal vs. Luminal A (HR: 9.12, p&lt;0.001) and tumor size &gt;2cm vs. ≤2cm (HR: 4.00, p=0.022) were significant prognostic factors for LRR as first failure. On multivariate analysis, only basal subtype (HR: 6.29, p=0.011) retained significance; others effects, including luminal B/HER2 combined subtypes, were not significant. Conclusions: Long-term clinical outcomes were excellent in this cohort of breast cancer patients treated with BCT and modern systemic therapy, with 10-year LRR 4.5% and OS 90.5%. Basal subtype was an independent predictor for LRR. Conversely, HER2+ subtype was not associated with increase in LRR, in this cohort treated with BCT and trastuzumab.
Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.
Authors: Anas Younes, Mark Kirschbaum, Lubomir Sokol, Lorrin Yee, Jorge Romaguera, Lovely Goyal, Cheng-Pang Hsu, Yuying Hwang, Kevin Gorski, Susan Wong, Darrin M. Beaupre
Journal: Blood (2009)
A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy
Authors: Jan de Jong, Peter Hellemans, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, Alexander Myasnikov, Dzhelil Osmanov, Raul Cordoba, Carlos Panizo, Loeckie de Zwart, Jan Snoeys, Vijay Chauhan, James Jiao, Juthamas Sukbuntherng, Daniele Ouellet
Journal: Blood (2016)
Correlation of radiotherapy with cause-specific and overall survival in clinically node-positive prostate cancer.
Authors: J. D. Tward, D. C. Shrieve
Journal: Journal of Clinical Oncology (2011)

9 Background: Clinically staged node-positive prostate adenocarcinoma is a rare entity. We evaluated the role of definitive radiotherapy (RT) in clinical N1 prostate cancer patients who did not undergo prostatectomy and compared their cause-specific (CSS) and overall (OS) survival to men who did not undergo any definitive therapy. Methods: Subjects were identified using the NCI's Surveillance, Epidemiology and End Results (SEER) Program diagnosed between the years 1988 and 2006 with adenocarcinoma of the prostate. Subjects included in the analysis were men with clinically staged node-positive disease, who were otherwise non-metastatic. Descriptive statistics were performed, and CSS and OS was estimated using the methods of Kaplan and Meier. Statistical comparisons of treatment modalities were analyzed using univariate and multivariate Cox regression. Results: A total of 1,100 subjects were identified. The median age was 69 yrs (range 41-95) and median f/u time was 90 months (range 1-255 months). The 5, 10 and 15 yr CSS for men who had no definitive therapy was 71.1%, 50.3% and 35.1% respectively. The 5, 10 and 15 yr CSS for men who had external beam RT was 78.1%, 62.9% and 51.4% respectively. This was significantly different favoring RT on univariate cox regression (Hazard Ratio (HR) =0.66, 95% CI=0.54 to 0.82, P = 0.0002). The 5, 10 and 15 yr OS for men who had no definitive therapy was 56.2%, 29.1% and 14.86% respectively. The 5, 10 and 15 yr OS for men who had external beam RT was 67.8%, 44.2% and 20.4% respectively. This difference was also significant favoring RT on univariate cox regression (HR =0.70, 95% CI 0.59 to 0.81, P &lt; 0.0001). On multivariate Cox regression analysis taking into account age at diagnosis, Gleason sum 2-4, 5-7, and 8-10, year of diagnosis, and presence or absence of definitive RT, RT (HR=0.69, 95% CI=0.56 to 0.86, P = 0.0008), earlier year of diagnosis (HR=0.94, 95% CI=0.92 to 0.97, P &lt; 0.0001), and GS 7 or less was correlated with improved CSS. Conclusions: RT for node-positive subjects is correlated with both clinically and statistically improved cause-specific and overall survival. Patients with clinical N1 prostate adenocarcinoma should be strongly considered for RT. No significant financial relationships to disclose.
Effect of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy.
Authors: Yousuke Nakai, Hiroyuki Isayama, Suguru Mizuno, Takashi Sasaki, Kazumichi Kawakubo, Hirofumi Kogure, Natsuyo Yamamoto, Naoki Sasahira, Kenji Hirano, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike
Journal: Journal of Clinical Oncology (2012)

309 Background: Non-anticancer drugs such as metformin or statin are reported to have a potential role in cancer treatment and we previously reported inhibition of renin-angiotensin system (RAS) by angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) lead to better prognosis in PaC receiving gemcitabine (Br J Cancer 103: 1644-8). The relation between diabetes (DM) with its medication and the incidence of PaC has been described but its impact on prognosis is still unclear. Methods: We retrospectively reviewed 250 pts with advanced PaC receiving chemotherapy with gemcitabine and/or S-1 between June 2001 and April 2011 with a median follow up of 9.9 months (Mo). Univariate and multivariate analyses of progression-free survival (PFS) and overall survival (OS) were performed in pts with and without DM, using age, gender, BMI, PS, stage, protocol, DM with its treatment, hypertension (HT) with its treatment, and use of statin as variables. Results: DM was diagnosed in 124 pts (49%) and was treated with insulin or insulin analogs (n = 59), sulfonylurea (n = 38), biguanide (n = 8), thiazolidinedione (n = 6), and alpha-glucosidase inhibitor (n = 5). Statin was used in 16 pts with DM and 14 pts without DM. Locally advanced disease (44% vs. 29%) and HT (44% vs. 28%) were more prevalent in pts with DM. PFS (6.3 vs. 4.9 Mo, P = 0.440) and OS (13.3 vs. 10.0 Mo, P = 0.084) was longer in pts with DM, though not significantly. Use of statin in pts with DM was associated with longer PFS (11.6 vs. 6.0 Mo, P = 0.034) and longer OS (25.4 vs. 11.3 Mo, P = 0.006), while PFS and OS did not differ by the use of statin in pts without DM. Multivariate subgroup analysis with and without DM showed metastatic disease (Hazard ratio [HR] 2.11, P = 0.001 and HR 1.57, P = 0.013), PS 0-1 (HR 0.08, P &lt;0.001 and HR 0.21, P &lt;0.001), use of ACEI/ARB (HR 0.60, P = 0.030 and HR 0.46, P = 0.031) as common prognostic factors for OS. Doublet chemotherapy (HR 0.48, P = 0.007) and use of statin (HR 0.40, P = 0.010) were prognostic only in pts with DM, but any medications for DM were not significant prognostic factors. Conclusions: In our retrospective analysis, use of statin in pts with DM as well as inhibition of RAS was associated with better prognosis in pts with PaC receiving chemotherapy.
Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia
Authors: Tiziano Barbui, Alessandro M. Vannucchi, Veronika Buxhofer-Ausch, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Elisa Rumi, Marco Ruggeri, Francesco Rodighiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, Guido Finazzi, Alessandra Carobbio, Juergen Thiele, Francesco Passamonti, Chiara Falcone, Ayalew Tefferi
Journal: Blood (2015)
Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer.
Authors: R. G. Bristow, A. S. Ishkanian, C. Malloff, M. Milosevic, M. Pintilie, T. van der Kwast, W. Lam
Journal: Journal of Clinical Oncology (2011)

42 Background: Biomarkers of local and systemic recurrence are needed to individualize patient risk categories and better define treatment. We hypothesized that genomic instability, as measured by percent genome alteration (PGA), can predict for biochemical failure in intermediate- risk prostate cancer. Methods: High-resolution array comparative genomic hybridization (arrayCGH) was used to identify PGA in frozen biopsies from 120 intermediate-risk prostate cancer patients. Our cohort included 39 T1c tumors, 78 T2 tumors and 2 T3 tumors. The Gleason score was 6 in 32 tumors, 7 in 82 tumors and 8–9 in 6 tumors. PSA ranged from 2.1–33 (median 8.0). Patients were treated with intensity-modulated radiotherapy (IMRT) with doses of 75.6–79.8 Gy in 1.8–2Gy fractions, or 60–66 Gy in 3 Gy fractions.. Twenty-five percent of patients also received neoadjuvant-concurrent bicalutamide (150mg po od). Biochemical failure, defined by Phoenix criteria or the initiation of salvage therapy, was observed in 35 patients after median follow-up of 5.4 years (range 0.9–8.8). Results: Array CGH showed variable PGA ranging from &lt;1% to 35% (median 6.7%). PSA and the use of hormonal therapy independently influenced biochemical relapse, and formed a baseline clinical model to which PGA was added. PGA was found to be a strong predictor of biochemical relapse (p&lt;0.0001) independent of the clinical prognostic factors (pre-treatment PSA, Gleason score and T-category). PGA was also found to be associated with unique tumour suppressor and oncogene gene loci clusters involved in genetic stability (e.g. loss of PTEN, p53, RB, NKX3.1, ATM, PARP-1 and gain of c-MYC; validated by in situ FISH). Conclusions: This is the first report to show genetic instability can independently predict for biochemical recurrence in intermediate-risk prostate cancer. Current studies are associating specific gene loci regions with clinical outcome. Our results could provide a way forward for individualized medicine for non-indolent prostate cancer based on initial daignostic biopsy material. Supported by Prostate Cancer Canada, The Terry Fox Foundation and the Canadian Cancer Society. No significant financial relationships to disclose.
Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation
Authors: Marco Mielcarek, Terrence Furlong, Paul V. O'Donnell, Barry E. Storer, Rainer F. Storb, Paul A. Carpenter, Paul J. Martin
Journal: Blood (2014)
A Retrospective Analysis Comparing BEAM Versus Melphalan Prior to First Autologous Peripheral Blood Hematopoietic Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients
Authors: Edward Anthony Faber, Fausto R. Loberiza, Mojtaba Akhtari, Philip Bierman, R. Gregory Bociek, Lori Maness, Julie M Vose
Journal: Blood (2011)
Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.
Authors: Matthew T Drake, Matthew J Maurer, Brian K Link, Ivana N Micallef, Thomas M Habermann, Jennifer L Kelly, William R Macon, Daniel Nikcevich, Joseph P Colgan, Cristine Allmer, Susan L Slager, George J Weiner, Thomas E Witzig, James R Cerhan
Journal: Blood (2009)
Evaluation of the role of second TUR for transurethral resection of bladder tumor in one piece (TURBO).
Authors: H. Ikeda, M. Nomura, T. Shou, K. Ishikawa, E. Kashiwagi, T. Dejima, H. Sanefuji, K. Okumura
Journal: Journal of Clinical Oncology (2011)

298 Background: Since transurethral resection of bladder tumor in one piece (TURBO) was reported in the Journal of Urology in 2000 by Ukai, some urologists carried out TURBO. We analyzed treatment results of TURBO in our hospital and examined the value of this procedure, especially for the pathological findings, recurrence and necessity of second TUR for TURBO. Methods: A total of 14 patients with bladder tumors carried out TURBO under spinal anesthesia, in some cases blocking the obtulater nerve, from April 2006 to June 2009 in our hospital. All cases were followed for over 1 year. The procedure is 1. point marking; 2. circular incision; 3. level incision; and 4. specimen retrieval using a needle electrode in accordance with the Ukai's method. We investigated pathological findings (margin situation), operation time, complications and recurrence. Results: It is possible to diagnose the precise pathlogical findings by TURBO. We judged the width and depth ew in sequential section. There were no complications during and after the operation. Operation time of TURBO (35–170 min) was longer than TUR-BT. Urethral catheter holding period and hospitalization period after TURBO was the same as TUR-BT. TURBO is a relatively safe procedure even for beginners. 5 cases had a recurrence in 13 cases. 2 cases had a recurrence in under 1 year, but the locations were other places. One case had a same place recurrence after 13 months. There were no cases of same place recurrence in under 1 year among margin-negative cases. Therfore we judged that ew-negative cases had no residual cancers. Conclusions: TURBO is a safe and useful procedure that provides precise pathological findings with minimal complications. Second TUR is not necessary for TURBO. TURBO has a possibility to be gold standard of the treatment for non-muscle invasive bladder cancer. No significant financial relationships to disclose.
Late CT surveillance in nonseminoma germ cell tumors (NSGCT).
Authors: M. Singhera, B. Johnson, V. Harris, A. Horwich, D. P. Dearnaley, R. A. Huddart
Journal: Journal of Clinical Oncology (2011)

223 Background: Testicular cancer is the commonest solid malignancy in 18-35 year old men. With the introduction of cisplatin, most patients with metastatic disease are cured.Over recent years a risk of late relapse (&gt;2 years after first line therapy) has been recognised in 2- 6% of NSGCTs. Appropriate follow-up strategies have not been determined. To investigate, the utility of long term CT surveillance we initiated a study to see if late CT could detect late relapses at an early stage. Methods: Eligible patients had been treated for Stage IM – Stage IV NSGCT diagnosed 5 years prior to entry. CT scans were at study entry and 5 years. Patients are reviewed annually with tumour markers and clinical examination. We plan to recruit 300 patients. This reports details the outcome of a planned interim analysis of the first round of screening after recruiting 100 patients Results: 108 patients have been enrolled into the study since 2006. Full clinical data was available for 88 patients. Median age was 31 years at diagnosis. 52 patients had evidence of teratoma differentiated (TD) in the primary.Stage at treatment was IM (1), II (45), III (6) and IV (36). Treatment was BEP [bleomycin, cisplatin and etopside (3 cycles: 30), (4 cycles: 20)], CBOP/BEP (16) and other platinum schedule (8) at diagnosis. 27 patients relapsed.Overall 38 had retroperitoneal lymph node.TD noted in 28. 10 had a metastatectomy [brain (2), pelvic mass (1:TD), pulmonary (6;TD:2), neck (2), iliac node (1:TD)]. Study scan was reported normal in 71 patients. None of these have relapsed however 1 patient died of interval lung cancer. Radiological abnormalities were identified in14 patients. 4 underwent surgery (3 RPLND and 1 lung nodule excision). 2 were benign and 2 had TD.1 patient had liver lesions proven to be cysts on ultrasound. 8 had small volume nodal abnormalities which are stable on repeat imaging. 1 is on annual CT surveillance for indeterminate lung nodules.4 patients are awaiting the initial study scan Conclusions: Late CT scan detected significant abnormalities in patients treated for NSGCT leading to surgery. Abnormalities not deemed appropriate for surgical intervention are being followed up surveillance scans. No significant financial relationships to disclose.
High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial
Authors: Andreas L Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzetkov, Rasa Griniute, Radka Oucheva, Thomas Grubinger, Marthin Kwakkelstein, Francesca Rancati, Günther A Gastl, Dominik Wolf
Journal: Blood (2010)